Idebenone loaded solid lipid nanoparticles interact with biomembrane models: calorimetric evidence.
The knowledge of the interactions between solid lipid nanoparticles (SLN) and cell membranes is important to develop effective carrier systems for drug delivery applications. Loading idebenone (IDE), an antioxidant drug useful in the treatment of neurodegenerative diseases, into SLN improves IDE antioxidant activity in in vitro biological studies, but the mechanism by which IDE permeation through the blood-brain barrier (BBB) occurs are still unclear. Therefore, in this research, unloaded and IDE loaded SLN interaction with biomembrane models, consisting of dimyristoylphosphatidylcholine multilamellar vesicles (MLV), were studied by differential scanning calorimetry (DSC). In the experiments performed, unloaded and IDE loaded SLN where incubated with the biomembrane models and their interactions were evaluated through the variations in their calorimetric curves. The results of our DSC studies indicated that the SLN under investigation were able to go inside the phospholipid bilayers with a likely localization in the outer bilayers of the MLV from where they moved toward the inner layers by increasing the contact time between SLN and MLV. Furthermore, IDE loaded SLN were able to release IDE into the biomembrane model, thus facilitating IDE penetration into the bilayers while free IDE showed only a low ability to interact with this model of biomembranes. Our results suggest that these SLN could be regarded as a promising drug delivery system to improve IDE bioavailability and antioxidant activity.
Department of Drug Sciences, University of Catania, V.le A. Doria 6, 95125 Catania, Italy. lmontene@unict.it
Lucia
L
Montenegro
Sara
S
Ottimo
Giovanni
G
Puglisi
Francesco
F
Castelli
Maria Grazia
MG
Sarpietro
D000975:Antioxidants / Q000008:administration & dosage / Q000737:chemistry; D001682:Biological Availability; D002151:Calorimetry / Q000379:methods; D002152:Calorimetry, Differential Scanning / Q000379:methods; D004134:Dimyristoylphosphatidylcholine / Q000737:chemistry / Q000378:metabolism; D016503:Drug Delivery Systems; D008055:Lipids / Q000008:administration & dosage* / Q000737:chemistry*; D008566:Membranes / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D008567:Membranes, Artificial; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry*; D010743:Phospholipids / Q000737:chemistry / Q000378:metabolism; D014451:Ubiquinone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics
D000975:Antioxidants; D008055:Lipids; D008567:Membranes, Artificial; D010743:Phospholipids; D014451:Ubiquinone; C036619:idebenone; D004134:Dimyristoylphosphatidylcholine